Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Verastem has two partnered RAMP programs that are targeting KRAS G12C-mutant NSCLC. RAMP 203 is in a Phase I/II trial of avutometinib in combination with Amgen’s KRAS G12C inhibitor LUMAKRAS.

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed ...

Verastem (VSTM) said late Tuesday it has dosed the first patient in its US phase 1/2a trial of VS-73 Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC ...

Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has completed the sale of Verastem's COPIKTRA, a marketed ...

Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells. For more ...

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven ...

BOSTON, December 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data ...

Verastem Inc. Annual stock financials by MarketWatch. View the latest VSTM financial statements, income statements and financial ratios.

Verastem Inc.VSTM-8.35%decrease; red down pointing triangle said Monday that it will wind down a midstage clinical trial of its experimental mesothelioma drug after an analysis showed the drug ...